Sands BE - Search Results

1

Effects of growth hormone secretion on body composition in patients with Crohn's disease.

Katznelson L, Fairfield WP, Zeizafoun N, Sands BE, Peppercorn MA, Rosenthal DI, Klibanski A. Katznelson L, et al. Among authors: sands be. J Clin Endocrinol Metab. 2003 Nov;88(11):5468-72. doi: 10.1210/jc.2003-030608. J Clin Endocrinol Metab. 2003. PMID: 14602791

2

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.

Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Sands BE, et al. Gastroenterology. 1999 Jul;117(1):58-64. doi: 10.1016/s0016-5085(99)70550-0. Gastroenterology. 1999. PMID: 10381910 Clinical Trial.

3

Medical therapy of steroid-resistant Crohn's disease.

Sands BE. Sands BE. Can J Gastroenterol. 2000 Sep;14 Suppl C:33C-37C. doi: 10.1155/2000/805015. Can J Gastroenterol. 2000. PMID: 11023559 Review.

4

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group. Sands BE, et al. Aliment Pharmacol Ther. 2002 Mar;16(3):399-406. doi: 10.1046/j.1365-2036.2002.01179.x. Aliment Pharmacol Ther. 2002. PMID: 11876692 Free article. Clinical Trial.

5

Risk of early surgery for Crohn's disease: implications for early treatment strategies.

Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK. Sands BE, et al. Am J Gastroenterol. 2003 Dec;98(12):2712-8. doi: 10.1111/j.1572-0241.2003.08674.x. Am J Gastroenterol. 2003. PMID: 14687822

6

Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.

Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Forcione DG, et al. Among authors: sands be. Gut. 2004 Aug;53(8):1117-22. doi: 10.1136/gut.2003.030734. Gut. 2004. PMID: 15247177 Free PMC article.

7

Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.

Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Sands BE, et al. J Clin Gastroenterol. 2006 Jul;40(6):482-9. doi: 10.1097/00004836-200607000-00005. J Clin Gastroenterol. 2006. PMID: 16825929 Clinical Trial.

8

An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele.

Forcione DG, Sands B, Isselbacher KJ, Rustgi A, Podolsky DK, Pillai S. Forcione DG, et al. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5094-8. doi: 10.1073/pnas.93.10.5094. Proc Natl Acad Sci U S A. 1996. PMID: 8643533 Free PMC article.

9

Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease.

Cariappa A, Sands B, Forcione D, Finkelstein D, Podolsky DK, Pillai S. Cariappa A, et al. Gut. 1998 Aug;43(2):210-5. doi: 10.1136/gut.43.2.210. Gut. 1998. PMID: 10189846 Free PMC article.

10

Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms.

Willett CG, Ooi CJ, Zietman AL, Menon V, Goldberg S, Sands BE, Podolsky DK. Willett CG, et al. Among authors: sands be. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):995-8. doi: 10.1016/s0360-3016(99)00374-0. Int J Radiat Oncol Biol Phys. 2000. PMID: 10705022

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

356 results

Search Page